News about "Serum Institute of India "

SII Invests in IntegriMedical to Boost N-FIS Technology

SII Invests in IntegriMedical to Boost N-FIS Technology

Serum Institute of India (SII) has made a strategic investment in IntegriMedical, acquiring a 20 percent stake in the company, to advance Needle-Free Injection System technology.

Serum Institute Of India | 18/05/2024 | By Aishwarya 114

SIIPL Signs Licensing Agreement with University of Oxford for Meningitis-B Vaccine

SIIPL Signs Licensing Agreement with University of Oxford for Meningitis-B Vaccine

Serum Institute of India Pvt. Ltd. (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation in a significant stride towards addressing the challenge of Men-B disease.

Serum Institute Of India | 22/04/2024 | By Aishwarya

SII Joins Hands with Univercells to Make Personalized Oncology Affordable

SII Joins Hands with Univercells to Make Personalized Oncology Affordable

The new therapies are developed using genetic material extracted from the patient’s tumors, a process which is both time-consuming, and expensive.

Serum Institute Of India | 12/04/2024 | By Manvi 194

Sanofi Receives Nod for IMOVAX-Polio in India

Sanofi Receives Nod for IMOVAX-Polio in India

Sanofi has gained approval for IMOVAX-Polio, an alternative injectable vaccine.

Serum Institute Of India | 11/04/2024 | By Aishwarya 140

Bharat Biotech Partners with Bilthoven Biologicals for Oral Polio Vaccines

Bharat Biotech Partners with Bilthoven Biologicals for Oral Polio Vaccines

Bharat Biotech has teamed up with Bilthoven Biologicals, a subsidiary of Serum Institute of India to produce and supply oral polio vaccines (OPVs) worldwide.

Serum Institute Of India | 05/04/2024 | By Aishwarya 179

Serum Institute of India to Launch Malaria Vaccine Soon

Serum Institute of India to Launch Malaria Vaccine Soon

This was announced by Managing Director Cyrus Poonawala during a press conference.

Serum Institute Of India | 01/09/2023 | By Manvi 419

Serum Institute claims COVID-19 vaccine to be market ready by 2022

Serum Institute claims COVID-19 vaccine to be market ready by 2022

Serum Institute had partnered with the US-based biotech drug research company Codagenix three weeks ago to jointly develop a live-attenuated vaccine to fight the coronavirus

Serum Institute Of India | 11/03/2020 | By Hemant 331


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members